Nature Reviews Clinical Oncology

Nature Reviews Clinical Oncology (commonly abbreviated as ''Nat. Rev. Clin. Oncol.') is a clinical review journal for oncologists and affiliated health-care professionals, published by Springer Nature. It was founded in 2004 as Nature Clinical Practice Oncology and took its present title in April 2009, with a 2025 impact factor of 94.6.Nature Reviews Clinical Oncology（常用缩写 Nat. Rev. Clin. Oncol.）是 Springer Nature 旗下面向肿瘤科医师及相关医疗从业者的临床类综述期刊，2004 年以 Nature Clinical Practice Oncology 之名创刊，2009 年 4 月改为现名，2025 年影响因子为 94.6。^[1]

Scope

• Disciplinary focus: clinical content is written by internationally renowned clinical academics and researchers, and the journal aims to be the premier source of reviews and commentaries for the scientific and clinical communities it serves. In-depth Reviews present authoritative and up-to-date information on a topic, Perspectives and News & Views articles carry topical discussion, and Research Highlights filter primary research from specialty and general medical journals.学科定位： 期刊由国际知名的临床学者与研究者撰写临床内容，目标是成为所服务科学界与临床界在综述与评论方面的首要来源，深度综述给出某一主题权威且与时俱进的介绍，观点与新闻与观点刊发话题性讨论，研究亮点则从专科与综合医学刊物中筛选一级研究；
• Audience: the content is intended for practising doctors, researchers and academics working within a specialty, with readers addressed from postgraduate level upwards, while the journal aims to make all its articles accessible to readers working in any medical discipline.读者对象： 主要供本专科的执业医师、研究者与临床学者阅读，读者定位自研究生层次起算，同时力求让任何医学学科的读者都能读懂其文章；
• Subjects covered: the scope includes epidemiology, screening, diagnosis, pathology, prevention, chemotherapy, radiotherapy, surgical oncology, medical oncology, targeted therapies, hormonal therapies, haematology, immunotherapy, imaging, palliative care, paediatric oncology, genetics and pharmacology, together with health services, economics and outcomes research.选题范围： 覆盖流行病学、筛查、诊断、病理学、预防、化疗、放疗、外科肿瘤学、内科肿瘤学、靶向治疗、激素治疗、血液学、免疫治疗、影像学、姑息治疗、儿科肿瘤学、遗传学与药理学，并纳入卫生服务、经济学与结局研究等领域；
• Commissioned model: articles written by external authors are invited or commissioned by the in-house editors, and authors may submit proposals for Review-type and Comment-type articles which the editors may formally commission. Complete unsolicited manuscripts are therefore not accepted.约稿定位： 外部作者撰写的文章由编辑部邀请或约稿，作者可提交综述类与评论类的选题提案并由编辑部决定是否正式约稿，期刊不接受直接投来的完整稿件；
• Open access: articles can only be published using the subscription route, and the publisher offers no immediate gold open access option and charges no publication fee. Six months after online publication, authors may self-archive the accepted manuscript on their personal website or in a funder or institutional repository.开放获取： 文章只能按订阅方式出版，出版方不提供立即开放获取选项，也不收取版面费；作者可在文章在线发表六个月后，将已接受的稿件存入个人主页或资助方与所属机构的知识库；

History

• 2004: the title was founded as Nature Clinical Practice Oncology, one of eight new clinical journals from Nature Publishing Group, positioned as a treatment-oriented oncology review journal with a bedside focus.2004年： 刊物以 Nature Clinical Practice Oncology 之名创刊，属自然出版集团新推的八本临床类刊物之一，定位为以治疗为导向、贴近临床床边的肿瘤学综述刊物。
• Division of labour with the basic-science journal: an editorial at launch stated that this title covers all of the clinical aspects of cancer and is more bedside-focused than its bench-oriented sister journal dealing with cancer biology and its therapeutic relevance. The two are editorially independent and complementary.与基础刊的分工： 创刊时期的编者按明确说明，本刊覆盖肿瘤学的全部临床面，较为贴近床边，与偏向实验台、关注癌症生物学及其治疗相关性的姊妹刊形成对照，两刊在编辑上彼此独立而定位互补。
• April 2009: the publisher rebranded eight clinical journals under the Nature Reviews name, expanding the series from seven titles to fifteen, and this title became Nature Reviews Clinical Oncology. The publisher stated that editorial scopes and commissioning strategies would not change and that the titles would retain their external Editors-in-Chief and international Advisory Boards.2009年4月： 出版方把八本临床类刊物统一改冠 Nature Reviews 品牌，系列规模由七本扩至十五本，本刊随之改名为 Nature Reviews Clinical Oncology；出版方同时说明这批刊物不改变编辑范围与约稿策略，并保留原有的外部主编与国际顾问委员会架构；
• Change of leadership: Diana Romero joined the editorial team in July 2015 and became Chief Editor in September 2017. She had obtained her PhD in biochemistry at the Universidad Autónoma de Madrid, working on the role of TGF-β in cancer progression.主编更替： Diana Romero 于 2015 年 7 月加入本刊编辑团队，2017 年 9 月升任主编；她此前在马德里自治大学取得生物化学博士学位，研究方向为转化因子在癌症进展中的作用。
• Impact and formats: the impact factor has risen steadily since launch, reaching 78.8 in 2022 and 94.6 in 2025, placing the journal near the top of the oncology category. Alongside Reviews and Perspectives it runs Comment and News & Views formats and organizes collections on themes such as rare cancers and precision oncology.影响与体裁： 期刊影响因子自创刊以来持续上行，2022 年达78.8，2025 年为 94.6，在肿瘤学类目中居于前列；除综述与观点外，另设评论与新闻与观点等体裁，并围绕罕见肿瘤、精准肿瘤学等专题组织专辑。^[2]

Editors

• Chief Editor: the journal is led by Diana Romero PhD, who joined in 2015 after postdoctoral research on prostate cancer at Imperial College London and became Chief Editor in September 2017. She is based in the London office.主编： 现任主编为 Diana Romero 博士，她在帝国理工学院完成前列腺癌方向的博士后研究后于 2015 年加入本刊，2017 年 9 月起出任主编，常驻伦敦办公室。
• Senior Editors: David Killock PhD and Peter Sidaway PhD serve as Senior Editors, based in the London and Berlin offices. The former trained in the mechanisms of leucocyte trafficking and the latter specialized in retinal neuroscience and autonomic neuropharmacology.高级编辑： David Killock 博士与 Peter Sidaway 博士担任高级编辑，两人分驻伦敦与柏林办公室，前者在加入本刊前曾有白细胞运输机制方面的博士训练，后者专攻视网膜神经科学与自主神经药理学；
• Advisory board and cross-journal team: the journal worked with an international Advisory Board of clinicians around the time of the rebranding, while day-to-day editorial work is now carried by the full-time professional editors named above, supported by a Reviews Cross-Journal Editorial Team that allocates resources across disciplines as needs arise.国际顾问委员会： 期刊改名前后与一支由临床医师组成的国际顾问委员会协作，改组后日常编辑工作由上述全职专业编辑团队承担，跨刊综述编辑团队则按需要在各学科之间调配人手。
• Submissions and contact: manuscripts and proposals are submitted through the Nature Publishing Group online submission and tracking system, and general editorial inquiries are addressed to the editorial team.投稿与联系： 稿件与选题提案通过自然出版集团的在线投稿与追踪系统提交，一般编辑问询由编辑部统一受理。
• Subscription options: the journal is published monthly in print and online, an online-only subscription is also available, and institutions can purchase online access in bulk through the group's licensing channels.订阅方式： 期刊以纸质与电子双版本每月出版，同时提供纯电子版订阅，机构可通过集团授权渠道批量购买在线访问权限。^[3]